Teplizumab (Tzield) to Delay Onset of Type 1 Diabetes
The Medical Letter on Drugs and Therapeutics · 2023
DOI: 10.58347/tml.2023.1667c ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Teplizumab-mzwv (Tzield – Provention Bio), an anti-CD3 monoclonal antibody, has been approved by the FDA to delay the onset of stage 3 type 1 diabetes in patients ≥8 years old who have stage 2 type 1 diabetes. It is the first drug to become available in the US that delays the onset of type 1 diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2023). Teplizumab (Tzield) to Delay Onset of Type 1 Diabetes. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1667c
Vancouver
Teplizumab (Tzield) to Delay Onset of Type 1 Diabetes. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1667c
BibTeX
@article{euvimed2023,
title = {Teplizumab (Tzield) to Delay Onset of Type 1 Diabetes},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2023},
doi = {10.58347/tml.2023.1667c}
}
EUVIMED